Cargando…

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate

Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC), combining a humanized monoclonal antibody (IgG1) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and a potent cytotoxic maytansinoid derivative, DM4, inhibiting microtubule assembly. SAR408701 is cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouzin, Clemence, Gibiansky, Leonid, Fagniez, Nathalie, Chadjaa, Mustapha, Tod, Michel, Nguyen, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098589/
https://www.ncbi.nlm.nih.gov/pubmed/35166967
http://dx.doi.org/10.1007/s10928-021-09799-0
_version_ 1784706419304431616
author Pouzin, Clemence
Gibiansky, Leonid
Fagniez, Nathalie
Chadjaa, Mustapha
Tod, Michel
Nguyen, Laurent
author_facet Pouzin, Clemence
Gibiansky, Leonid
Fagniez, Nathalie
Chadjaa, Mustapha
Tod, Michel
Nguyen, Laurent
author_sort Pouzin, Clemence
collection PubMed
description Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC), combining a humanized monoclonal antibody (IgG1) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and a potent cytotoxic maytansinoid derivative, DM4, inhibiting microtubule assembly. SAR408701 is currently in clinical development for the treatment of advanced solid tumors expressing CEACAM5. It is administered intravenously as a conjugated antibody with an average Drug Antibody Ratio (DAR) of 3.8. During SAR408701 clinical development, four entities were measured in plasma: conjugated antibody (SAR408701), naked antibody (NAB), DM4 and its methylated metabolite (MeDM4), both being active. Average DAR and proportions of individual DAR species were also assessed in a subset of patients. An integrated and semi-mechanistic population pharmacokinetic model describing the time-course of all entities in plasma and DAR measurements has been developed. All DAR moieties were assumed to share the same drug disposition parameters, excepted for clearance which differed for DAR0 (i.e. NAB entity). The conversion of higher DAR to lower DAR resulted in a DAR-dependent ADC deconjugation and was represented as an irreversible first-order process. Each conjugated antibody was assumed to contribute to DM4 formation. All data were fitted simultaneously and the model developed was successful in describing the pharmacokinetic profile of each entity. Such a structural model could be translated to other ADCs and gives insight of mechanistic processes governing ADC disposition. This framework will further be expanded to evaluate covariates impact on SAR408701 pharmacokinetics and its derivatives, and thus can help identifying sources of pharmacokinetic variability and potential efficacy and safety pharmacokinetic drivers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10928-021-09799-0.
format Online
Article
Text
id pubmed-9098589
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-90985892022-05-14 Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate Pouzin, Clemence Gibiansky, Leonid Fagniez, Nathalie Chadjaa, Mustapha Tod, Michel Nguyen, Laurent J Pharmacokinet Pharmacodyn Original Paper Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC), combining a humanized monoclonal antibody (IgG1) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and a potent cytotoxic maytansinoid derivative, DM4, inhibiting microtubule assembly. SAR408701 is currently in clinical development for the treatment of advanced solid tumors expressing CEACAM5. It is administered intravenously as a conjugated antibody with an average Drug Antibody Ratio (DAR) of 3.8. During SAR408701 clinical development, four entities were measured in plasma: conjugated antibody (SAR408701), naked antibody (NAB), DM4 and its methylated metabolite (MeDM4), both being active. Average DAR and proportions of individual DAR species were also assessed in a subset of patients. An integrated and semi-mechanistic population pharmacokinetic model describing the time-course of all entities in plasma and DAR measurements has been developed. All DAR moieties were assumed to share the same drug disposition parameters, excepted for clearance which differed for DAR0 (i.e. NAB entity). The conversion of higher DAR to lower DAR resulted in a DAR-dependent ADC deconjugation and was represented as an irreversible first-order process. Each conjugated antibody was assumed to contribute to DM4 formation. All data were fitted simultaneously and the model developed was successful in describing the pharmacokinetic profile of each entity. Such a structural model could be translated to other ADCs and gives insight of mechanistic processes governing ADC disposition. This framework will further be expanded to evaluate covariates impact on SAR408701 pharmacokinetics and its derivatives, and thus can help identifying sources of pharmacokinetic variability and potential efficacy and safety pharmacokinetic drivers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10928-021-09799-0. Springer US 2022-02-15 2022 /pmc/articles/PMC9098589/ /pubmed/35166967 http://dx.doi.org/10.1007/s10928-021-09799-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Pouzin, Clemence
Gibiansky, Leonid
Fagniez, Nathalie
Chadjaa, Mustapha
Tod, Michel
Nguyen, Laurent
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
title Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
title_full Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
title_fullStr Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
title_full_unstemmed Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
title_short Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
title_sort integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a dm4 anti-ceacam5 antibody-drug conjugate
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098589/
https://www.ncbi.nlm.nih.gov/pubmed/35166967
http://dx.doi.org/10.1007/s10928-021-09799-0
work_keys_str_mv AT pouzinclemence integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate
AT gibianskyleonid integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate
AT fagnieznathalie integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate
AT chadjaamustapha integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate
AT todmichel integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate
AT nguyenlaurent integratedmultipleanalytesandsemimechanisticpopulationpharmacokineticmodeloftusamitamabravtansineadm4anticeacam5antibodydrugconjugate